AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
The pharmaceutical market is currently defined by a race to replace aging blockbusters with next-generation therapies. Deciding whether…
Eli Lilly CEO still wants deal to bring Mounjaro to Australia under PBS
Eli Lilly pharmaceuticals CEO David Ricks says he still wants to reach an agreement with the Australian government…
Medicare’s Drug-Pricing Proposal Carries A Hidden Cost
“CMS’s proposal would encourage one thing above all else: investing less in improving existing medicines,” says health expert…
Semaglutide Generics Surge in Sales Despite Supply Challenges, ETPharma
New Delhi: After a brief slowdown, sales of generic versions of the weight-loss drug semaglutide recorded a strong…
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
Quick Read LLY raised 2026 guidance to $82B-$85B as Mounjaro and Zepbound surged, while NVO guided to an…
Will Mounjaro & Zepbound Drive Lilly’s Q2 Results: Buy, Sell or Hold?
Eli Lilly and Company LLY will report its second-quarter 2026 earnings on Aug. 5, before market open. The Zacks…
‘Super weight loss’ drug retatrutide could be available soon
KENT COUNTY, Mich — A new weight loss drug could soon be joining the growing list of medications…
Is Eli Lilly (LLY) Undervalued After Novo Nordisk’s GLP 1 Advertising Lawsuit?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Lilly to file for next-gen obesity drug approval in early 2027
Investing.com — Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in…
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Topline Eli Lilly, the GLP-1 maker behind Mounjaro and Zepbound, said it would file for Food and Drug…
Does EU Approval of Wegovy Pill Change NVO’s Competitive Story?
Novo Nordisk NVO received a meaningful commercial boost last week after the European Commission approved the oral version of…
Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…